BRPI9917863B8 - composição farmacêutica que é uma vacina - Google Patents

composição farmacêutica que é uma vacina

Info

Publication number
BRPI9917863B8
BRPI9917863B8 BRPI9917863A BR9917863A BRPI9917863B8 BR PI9917863 B8 BRPI9917863 B8 BR PI9917863B8 BR PI9917863 A BRPI9917863 A BR PI9917863A BR 9917863 A BR9917863 A BR 9917863A BR PI9917863 B8 BRPI9917863 B8 BR PI9917863B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
vaccine
leishmaniasis
chimera
animal
Prior art date
Application number
BRPI9917863A
Other languages
English (en)
Other versions
BRPI9917863B1 (pt
BRPI9917863C1 (pt
BRPI9917863A2 (pt
Inventor
Bedate Alonso Carlos
Original Assignee
Leti Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leti Lab filed Critical Leti Lab
Priority claimed from PCT/EP1999/010441 external-priority patent/WO2000039298A1/en
Publication of BRPI9917863A2 publication Critical patent/BRPI9917863A2/pt
Publication of BRPI9917863B1 publication Critical patent/BRPI9917863B1/pt
Publication of BRPI9917863C1 publication Critical patent/BRPI9917863C1/pt
Publication of BRPI9917863B8 publication Critical patent/BRPI9917863B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA A presente invenção se refere a uma composição farmacêutica para a prevenção e tratamento, humano ou animal, de Leishmaniose. A composição farmacêutica contém a proteína Quimera Q, que é o produto de umgene quimérico codificando a determinação antigênica de quatro proteínas de Leishmaniose infantum.
BRPI9917863A 1998-12-23 1999-12-23 composição farmacêutica que é uma vacina BRPI9917863B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11382598P 1998-12-23 1998-12-23
CA2256124A CA2256124C (en) 1998-12-23 1998-12-23 Chimeric gene formed of the dna sequences that encode the antigenic determinants of four proteins of l. infantum, and protein encoded by said gene, and pharmaceutical composition useful for preventing and/or treating leishmaniosis in animals or humans
PCT/EP1999/010441 WO2000039298A1 (en) 1998-12-23 1999-12-23 Chimeric gene encoding the antigenic determinants of four proteins of l. infantum
BRPI9916549 1999-12-23

Publications (4)

Publication Number Publication Date
BRPI9917863A2 BRPI9917863A2 (pt) 2010-12-21
BRPI9917863B1 BRPI9917863B1 (pt) 2016-08-02
BRPI9917863C1 BRPI9917863C1 (pt) 2021-05-25
BRPI9917863B8 true BRPI9917863B8 (pt) 2022-08-30

Family

ID=27671952

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9917863A BRPI9917863B8 (pt) 1998-12-23 1999-12-23 composição farmacêutica que é uma vacina

Country Status (5)

Country Link
JP (1) JP4883839B2 (pt)
BR (1) BRPI9917863B8 (pt)
CA (1) CA2256124C (pt)
RS (1) RS50013B (pt)
ZA (1) ZA200105994B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187751B2 (en) * 2010-11-10 2015-11-17 Laboratorios Leti, S.L. Adjuvant

Also Published As

Publication number Publication date
CA2256124A1 (en) 2000-06-23
ZA200105994B (en) 2002-07-22
CA2256124C (en) 2015-06-16
RS50013B (sr) 2008-09-29
BRPI9917863B1 (pt) 2016-08-02
YU51601A (sh) 2005-07-19
JP4883839B2 (ja) 2012-02-22
BRPI9917863C1 (pt) 2021-05-25
BRPI9917863A2 (pt) 2010-12-21
JP2002533474A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
LU93259I2 (fr) LETIFEND (Protein Q)
BR0016022A (pt) Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
EP1539228A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
PT832081E (pt) Compostos biciclicos aromaticos
ES2195555T3 (es) Empleo de composiciones para proporcionar glutamina.
DE69703820T2 (de) Diaromatische propynyl- oder dienylverbindungen
DE60218636D1 (de) Antikörper zur vorbeugung und behandlung von e. coli aeec krankheiten
BRPI0418854A (pt) composições herbáceas
BRPI9917863B8 (pt) composição farmacêutica que é uma vacina
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
BRPI0418017A (pt) medicamento compreendendo inibidores de pentraxina ptx3 longa
BR0309966A (pt) Muteìnas de fator de crescimento placentário tipo 1, método de preparação e seus usos
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
BRPI0412477A (pt) aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
ATE27822T1 (de) Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus.
BR0312267A (pt) Variantes do polipepìdeo papm de bactérias do gênero streptomices

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23/12/2019

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B21I Extinguishment of a patent or of a certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 21.1 NA RPI NO 2630 DE 01/06/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2415, DE 18/04/2017. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 02/08/2016 OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2378 DE 02/08/2016, QUANTO A PAGINA DA REIVINDICACAO). PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.?

B25D Requested change of name of applicant approved